WTR Small-Cap Spotlight

Send us Fan Mail

BLGO’s CEO Dennis Calvert joins Dmitry Silversteyn and Tim Gerdeman to discuss the company’s science-driven approach to developing and commercializing innovative solutions to address critical environmental problems such as “forever chemicals”, air and water quality and cost-effective power storage.

Send us Fan Mail

Join WTR’s Tim Regan, Curtis Shauger, Dr. John Roy and as they chat about Crypto, AI, and the recent WTR AI and Technology Investor Conference.

Send us Fan Mail

In this special episode, Nicole is joined by industry experts Tim Regan and Tim Gerdeman from Water Tower Research. Together, they embark on a dynamic conversation delving into the latest trends, challenges, and opportunities in women's health. They discuss continued progress on the markets adoption of the Company’s OvaSuite products and other areas of growth for AWH. 

Send us Fan Mail

TMC’s CFO Craig Shesky and the company’s Head of Stakeholder Engagement Corey McLachlan join WTR’s Dmitry Silversteyn and Tim Gerdeman to discuss the importance of deep-sea mining as a source of critical metals for global energy transition with the least possible negative impact on the planet and the people, and look at the current state of the industry, political tailwinds, and changes in public attitudes toward the industry.

Send us Fan Mail

Join WTR’s Tim Regan and Dr. John Roy and as they chat about Crypto and AI, and the hype surrounding it, and which Crypto and AI companies are presenting at the WTR AI and Technology Investor Conference on April 10 and 11th. 

Send us Fan Mail

Canada-based PharmAla Biotech's Founding CEO and President Nick Kadysh joins WTR's Tim Regan and Robert Sassoon to discuss PharmAla's  focus on MDMA, the regulatory environment, and the company's recipe for success in the psychedelics space. Founded three years ago,  the company reported annualized revenue of C$3 million and achieved a first-time profit for its most recent reported quarter. 

Send us Fan Mail

Doug talks about factors impacting the very soft start to 2024 for the publicly traded direct selling stocks, with forward earnings being sharply reduced coming out of the 2023 4Q earnings cycle and forward multiples remaining at generational lows.  However, Doug notes that these companies have been around for a while and have seen tough stretches before, and successfully managed through.

Send us Fan Mail

Tim Regan is joined by Peter Gastreich and Chris Degner to discuss the changing landscape for the oil & gas industry in Latin America and Colombia. Among the key themes discussed include strategies of onshore independent operators and natural gas in the context of energy transition.

Send us Fan Mail

WTR’s Tim Regan and Jesse Redmond were joined by Benzinga’s Elliot Lane to recap the company’s recent Cannabis Spotlight event in Los Angeles. This was Benzinga’s first regional event, and the group discussed the sentiment among operators, favorite moments, and biggest takeaways. The episode concludes by looking forward to Benzinga’s Cannabis Capital Conference in Hollywood, Florida, in April. 

Send us Fan Mail

BayMedica is the commercial business arm of rare cannabinoids-based drug developer InMed Pharmaceuticals (NASDAQ: INM). BayMedica produces and sells synthesized high purity and consistent rare cannabinoid ingredients to the Health & Wellness sector. BayMedica’s business has quickly grown its annual revenues to more than $5 million over the last 12 months.